Special paperCan positron emission tomography (PET) be used to detect subclinical response to cancer therapy?
References (14)
- et al.
Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose
J Nucl Med
(1978) - et al.
The applications of PET in clinical oncology
J Nucl Med
(1991) - et al.
The promise of FDG in diagnosis and surveillance of head and neck cancer
Cancer
(1994) - et al.
FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy
J Nucl Med
(1994) - et al.
Glucose utilisation of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography
Neurology
(1982) - et al.
Uptake of carbon-11-methionine and fluorodeoxyglucose in non Hodgkins's lymphoma: a PET study
J Nucl Med
(1991) - et al.
Metabolic imaging of human extremity musculoskeletal tumours by PET
J Nucl Med
(1988)
Cited by (100)
A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma
2022, Seminars in Nuclear MedicineCitation Excerpt :This was considered with the adjustment that the point of best overall response (BOR) can be reached even after a previous exam that already showed a progressive disease (PD). 18F-fluorodeoxyglucose (FDG) uptake detected in positron emission tomography and/or computed tomography (PET/CT) enables response assessment sooner after starting a therapy compared to classical CT criteria like RECIST; declining uptake of the tumor lesions due to cancer cell death is often detectable before the corresponding anatomical change becomes measurable.38 There are two major response criteria designed for PET diagnostic in widespread use today: The EORTC criteria, named after the European Organization for Research and Treatment of Cancer (EORTC) PET study group, were published in 199939 and PET Response Criteria in Solid Tumors (PERCIST) proposed by Wahl et al. in 2009.40
Changes in cervical cancer FDG uptake during chemoradiation and association with response
2013, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :This difference may be due to the timing of the PET scans during therapy or differences in pretreatment tumor volumes and SUVmax. Other studies have also suggested that FDG uptake decreases earlier than tumor shrinkage (16, 17). In previous research that included later during-treatment PET imaging, 6 cervical patients were observed to have a CMR during treatment (18).
PET and PET-CT Imaging in Treatment Monitoring of Breast Cancer
2009, PET ClinicsCitation Excerpt :This approach works well for some sites of metastatic disease, such as the liver and lungs, but regional nodal disease and bones are difficult to evaluate.55 These limitations of CT/MRI can be effectively overcome by functional imaging techniques, which have the unique ability to detect subclinical alterations in tumor physiology and biochemistry resulting from efficacious therapy.56 Besides this, 18F-FDG PET also identified patients with low tumor metabolic activity before treatment as not achieving histopathologic response, suggesting that breast cancers with low metabolic activity are not likely to respond to primary chemotherapy, thus guiding initial management.40–42,57
PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer
2008, PET ClinicsCitation Excerpt :The most important step in the evaluation of treatment response is the identification of nonresponders as early as possible after the initiation of chemotherapy so that expensive, ineffective, and toxic drugs can be discontinued and alternative treatment methods instituted. Limitations of CT and MR imaging can be overcome by functional imaging techniques that can detect subclinical alterations in tumor metabolism resulting from therapy.63 FDG PET has been used to assess the response of tumor during and after completion of treatment of breast cancer.64–66
Ita-immuno-pet: the Role of Fdg Pet/ct for Assessing Response to Immunotherapy
2022, Research Square